Soft tissue robotic systems designed to improve surgical precision are expanding into new specialties and increasing competition for longtime industry leader Intuitive Surgical.
Intuitive Surgical (Nasdaq: ISRG)+
has received FDA clearance for “several cardiac procedures,” CEO Dave Rosa said today while announcing the surgical robotics company’s latest financial and operating results.
Retinal vein occlusion (RVO) is a severe disease that occurs when a vein in the light-sensitive layer at the back of the eye (i.e., the retina) becomes blocked, which results in a loss of vision. There are currently a few medical interventions that address RVO, including the periodic injection of medications that block the abnormal growth of blood vessels or of steroids, which reduce swelling and inflammation.
EndoQuest Robotics announced today that the FDA approved the initiation of the next and final stage of its PARADIGM trial.
IotaMotion announced today that it received FDA 510(k) clearance for expanded pediatric use of its iotaSoft insertion system.
CMR Surgical announced today that it received CE mark and U.K. approval for its Versius surgical robot in pediatric surgery.
Social robots are efficacious and effective for children with autism, according to a study published online Dec. 24 in Science Robotics.
CMR gained FDA marketing authorization for its first-generation Versius robot in October 2024 through the de novo pathway. In April, the company said it raised more than $200 million to support the commercialization of Versius.
Intuitive (NASDAQ: ISRG)+
announced today that the FDA cleared its da Vinci single port (SP) surgical robot for use in new types of procedures.
Medical Microinstruments (MMI) announced today that the FDA granted 510(k) clearance for its NanoWrist surgical robot instruments.